New Treatment Advances & Current Management Approaches in Acute Kidney Injury-Hepatorenal Syndrome (AKI-HRS)

New Treatment Advances & Current Management Approaches in Acute Kidney Injury-Hepatorenal Syndrome (AKI-HRS).

Beginning Date: 01/23/2020
Ending Date: 12/31/2020

Target Audience:
This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, hospitalists/intensive care specialists, nephrologists, nurse practitioners (NPs), physician assistants (PAs), nurses (RNs) and other healthcare professionals involved in the care of patients with Hepatorenal syndrome (HRS).

Accreditation:
Credit Designation:
Purdue University College of Pharmacy designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Objectives:
Upon completion of this educational activity, participants should be able to:
• Define the types of HRS, its prevalence rates, and proposed pathophysiology
• Discuss the International Club of Ascites (ICA) criteria for the diagnosis and management of acute kidney injury (AKI) in cirrhosis and apply these criteria in clinical practice
• Review the clinical signs of HRS and recognize the differing treatment goals in HRS (i.e. long-term treatment improvement of liver function vs. short term improvement of kidney function)
• Recognize the need for approved therapies for HRS in the U.S. and apply recommended treatment strategies to clinical practice in the absence of these therapies
• Identify new advancements in the treatment of HRS

Additional details will be posted as soon as information is available.